Abstracts

Inflammatory Signatures Predict the Risk of Severe Non-AIDS Events, Especially Non-AIDS Cancers

Background: While elevated levels of inflammatory biomarkers in people with HIV (PWH) have consistently been linked to a higher risk of severe non-AIDS adverse events (SNAEs), their clinical significance and the relevant inflammatory pathways are not well-established. Methods: In this nested case-control study within the Spanish AIDS Research Cohort (CoRIS), from a pool of 18,573…

Description of Clonal Hematopoiesis in a Hospital-Based Cohort of People Living With HIV

Background: In the antiretroviral therapy era, the population of people living with HIV (PLWH) is aging, with increased mortality from chronic diseases and non-AIDS defining cancers. Similarly, clonal hematopoiesis (CH) has been associated with both malignancy and cardiovascular disease in the non-HIV population. Clonal hematopoiesis has been described as infrequent in patients under 50 and…

WT1 Upregulation by Lytic Induction of Kaposi Sarcoma Herpesvirus

Background: Kaposi Sarcoma herpesvirus (KSHV or HHV8) is the etiologic agent of Kaposi sarcoma and is associated with Multicentric Castleman disease and Primary effusion lymphoma. KSHV demonstrates two different phases of infection in the host: latent and lytic which are both essential to KSHV pathogenesis. The viral protein regulator or transcription activator (RTA) is required…

Monthslong HBV Suppression by TFV Double Ester Prodrugs

Background: Tenofovir (TFV) prodrugs [TFV disoproxil-/TFV alafenamide- fumarates (TDF/TAF)] are recommended daily oral treatments for chronic hepatitis B (HBV) infection. Given the growing popularity of long-acting (LA) therapies for treatment of chronic viral infections, an ever increasing number of potent medicines will come available. One, developed in our own laboratories, is a lipophilic ProTide of…

Hepatitis B Reactivation in PLWH With Anti-Core Antibody After Switch to an Anti-HBV Sparing Regimen

Background: Anticore antibody (antiHBc) in absence of hepatitis B surface antigen (HBsAg) is defined as an isolated antiHBc status that may be associated with HBV reactivation. We decided to investigate HBV reactivation in antiHBc-PLWH (with isolated anti-HBc or with anti-HBc and anti-HBsAg) after the switch from ART including drugs active on both viruses (tenofovir disoproxil…

Transaminase Elevations Among Patients With Occult HBV Infection on 2-Drug Antiretroviral Regimens

Background: Concerns have been raised about the possibility of hepatitis reactivation among individuals with occult HBV infection (OHBVI) who discontinue antiretroviral agents with anti-HBV activity. Whether OHBVI is associated with increased risk of transaminase elevation among those switching to two-drugs regimens (2DR), discontinuing lamivudine (3TC) and/or tenofovir (TFV), merits to be investigated. Methods: People living…